The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome.
BACKGROUND
To evaluate the prognostic value of early and intensive lipid-lowering treatment on ventricular premature beat or nonsustained ventricular tachycardia (NSVT) after acute coronary syndrome (ACS) (ST-elevation myocardial infarction [STEMI], non-STEMI, and unstable angina pectoris).


OBJECTIVE
Provided that early and intensive lipid-lowering treatment can reduce ventricular premature beat or non-sustained ventricular tachycardia after ACS.


METHODS
A total of 586 patients with ACS were randomly divided into 2 groups: group A (with conventional statin therapy, to receive 10 mg/day atorvastatin, n = 289) and group B (early and intensive statin therapy, 60 mg immediately and 40 mg/day atorvastatin, n = 297). The frequency of ventricular premature beat and NSVT was recorded with Holter monitoring after hospitalization (24 hours and 72 hours).


RESULTS
Seventy-seven (11.8%) patients had NSVT. When compared to patients with no documented NSVT, patients with NSVT were older and more often had myocardial infarction, diabetes mellitus, atrial fibrillation, and an ejection fraction < 40% in their history. Ventricular premature beats decreased significantly in the early and aggressive treatment group (24 hours, P < 0.01; 72 hours, P < 0.001). A significant reduction in NSVT was seen in the early and aggressive (24 hours, P < 0.01; 72 hours, P < 0.001) group. No side effects were observed in either group.


CONCLUSIONS
Early and intensive lipid-lowering treatment can obviously decrease ventricular premature beats and NSVT.
Department of Cardiology, Longgang District Central Hospital of Shenzhen, Guangdong, China. wxinh@21cn.com
Xian-Zhi
XZ
He
Sheng-Hua
SH
Zhou
Xin-Hong
XH
Wan
Hai-Yu
HY
Wang
Qing-Hua
QH
Zhong
Jian-Fang
JF
Xue
D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy*; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D016009:Chi-Square Distribution; D002681:China; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D015716:Electrocardiography, Ambulatory; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*; D018570:Risk Assessment; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome; D018879:Ventricular Premature Complexes / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin
JAMA. 2004 Sep 15;292(11):1307-16
15337732
Cardiovasc Res. 2006 Mar 1;69(4):798-807
16405931
J Pharmacol Exp Ther. 2005 Dec;315(3):1109-18
16109744
Circulation. 2004 Aug 31;110(9):1061-8
15326073
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
16341063
Int J Cardiol. 2003 Jul;90(1):63-72
12821221
J Am Coll Cardiol. 2003 Jul 2;42(1):81-7
12849664
JAMA. 2006 May 3;295(17):2046-56
16670413
J Am Coll Cardiol. 2005 Nov 15;46(10):1855-62
16286171
Nat Rev Immunol. 2006 May;6(5):358-70
16639429
Circulation. 2002 Nov 19;106(21):2694-9
12438295
Eur J Pharmacol. 2005 Dec 28;528(1-3):17-26
16316648
Arch Intern Med. 2006 Sep 25;166(17):1814-21
17000936
Eur Heart J. 2001 Aug;22(16):1374-450
11482917
Circulation. 2003 May 20;107(19):2493-8
12695293
Anesthesiology. 2005 Dec;103(6):1156-66
16306727
Br J Clin Pharmacol. 2004 May;57(5):640-51
15089818
J Am Coll Cardiol. 2001 Mar 15;37(4):1093-9
11263614
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
Physiol Rev. 2005 Oct;85(4):1205-53
16183911
Br J Pharmacol. 2005 Jan;144(1):59-70
15644869
JAMA. 2006 Apr 5;295(13):1556-65
16533939
Circulation. 2006 May 16;113(19):2363-72
16702489
Mol Pharmacol. 2006 Oct;70(4):1204-11
16835355
Z Kardiol. 2003 Feb;92(2):164-72
12596078
N Engl J Med. 2004 Apr 8;350(15):1495-504
15007110
Biophys J. 2006 Jun 1;90(11):4060-70
16513788